UY38971A - Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso - Google Patents

Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso

Info

Publication number
UY38971A
UY38971A UY0001038971A UY38971A UY38971A UY 38971 A UY38971 A UY 38971A UY 0001038971 A UY0001038971 A UY 0001038971A UY 38971 A UY38971 A UY 38971A UY 38971 A UY38971 A UY 38971A
Authority
UY
Uruguay
Prior art keywords
compounds
delta
methods
heterocyclic compounds
desaturase inhibitors
Prior art date
Application number
UY0001038971A
Other languages
English (en)
Spanish (es)
Inventor
Elena Minatti Ana
Paul Bourbeau Matthew
Rebecca Allen Jennifer
Paolo Vincetti
Michela Beltrani
Teodora DAMYANOVA
Iain Lingard
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY38971A publication Critical patent/UY38971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001038971A 2019-11-25 2020-11-25 Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso UY38971A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25

Publications (1)

Publication Number Publication Date
UY38971A true UY38971A (es) 2021-06-30

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038971A UY38971A (es) 2019-11-25 2020-11-25 Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso

Country Status (21)

Country Link
US (3) US11512097B2 (https=)
EP (1) EP4065223A1 (https=)
JP (2) JP7254246B2 (https=)
KR (2) KR102598203B1 (https=)
CN (2) CN114728167B (https=)
AR (1) AR120556A1 (https=)
AU (1) AU2020392087B2 (https=)
BR (1) BR112022010054A2 (https=)
CA (1) CA3162281A1 (https=)
CL (2) CL2022001357A1 (https=)
CO (1) CO2022008690A2 (https=)
CR (1) CR20220308A (https=)
IL (1) IL293191B2 (https=)
JO (1) JOP20220125A1 (https=)
MX (1) MX2022006281A (https=)
PE (1) PE20231097A1 (https=)
PH (1) PH12022551282A1 (https=)
SA (1) SA522432710B1 (https=)
TW (2) TWI867822B (https=)
UY (1) UY38971A (https=)
WO (1) WO2021108408A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11220510B2 (en) * 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
KR102598203B1 (ko) 2019-11-25 2023-11-03 암젠 인크 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
WO2024112763A1 (en) 2022-11-23 2024-05-30 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
EP0242690B1 (en) 1986-04-07 1993-06-30 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
DE60022769T2 (de) 1999-10-15 2006-07-06 Neurocrine Biosciences, Inc., San Diego Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
AU2005317928B2 (en) 2004-12-24 2010-06-10 Astrazeneca Ab Heterocyclic compounds as CCR2b antagonists
CA2612585A1 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
BRPI0614158A2 (pt) 2005-07-27 2016-11-22 Basf Ag compostos, processo para reparar compostos, agente fungicida, semente, e, processo para combater fungos nocivos fitopatogênicos
EP1915376B1 (de) 2005-07-27 2009-09-09 Basf Se Fungizide 6-phenyl-pyrazolopyrimidin-7-ylamine
AU2006274075A1 (en) 2005-07-27 2007-02-01 Basf Se Fungicide 6-phenyl-triazolopyrimidinyl amines
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
EP2074127A1 (en) 2006-09-28 2009-07-01 Novartis AG Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use
CN101522676A (zh) 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
WO2008057601A2 (en) 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
AU2008206921B2 (en) 2007-01-19 2012-11-01 Basf Se Fungicidal mixtures of 1-methylpyrazole-4-ylcarboxylic acid anilides and azolopyrimidinylamines
EP2131658A2 (en) 2007-01-30 2009-12-16 Basf Se Method for improving plant health
BRPI0809045A2 (pt) 2007-03-23 2014-09-02 Basf Se Combinações de substância ativa, uso de combinações de substância ativa, métodos para combater fungos fitopatogênicos indesejáveis, para preparar agentes pesticidas, e para tratar sementes, e, produto de revestimento de semente
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2719362A1 (en) * 2008-04-04 2009-10-08 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100099561A1 (en) 2008-10-15 2010-04-22 E.I. Du Pont De Nemours And Company Heterobicyclic alkylthio-bridged isoxazolines
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2012011592A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 複素環化合物およびその用途
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2013177538A2 (en) 2012-05-24 2013-11-28 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
MX2016002794A (es) 2013-09-05 2016-09-13 Genentech Inc Compuestos antiproliferativos.
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
BR112016024455B1 (pt) 2014-04-23 2023-02-07 Mitsubishi Tanabe Pharma Corporation Composto heterocíclico bicíclico ou tricíclico
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
JP2017091808A (ja) 2015-11-10 2017-05-25 株式会社フジクラ 酸化物超電導線材の製造方法及び超電導コイルの製造方法
US11414385B2 (en) 2015-12-21 2022-08-16 The University Of Chicago Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
SG11201910197SA (en) 2017-05-15 2019-11-28 Dana Farber Cancer Inst Inc Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020002869A (es) 2017-09-15 2020-07-24 Aduro Biotech Inc Compuestos de pirazolopirimidinona y usos de los mismos.
KR102598203B1 (ko) * 2019-11-25 2023-11-03 암젠 인크 델타-5 불포화효소 억제제로서의 헤테로시클릭 화합물 및 사용 방법

Also Published As

Publication number Publication date
JP7254246B2 (ja) 2023-04-07
JP2022549739A (ja) 2022-11-28
JOP20220125A1 (ar) 2023-01-30
BR112022010054A2 (pt) 2022-08-16
CA3162281A1 (en) 2021-06-03
MX2022006281A (es) 2022-06-08
IL293191B1 (en) 2025-05-01
CN114728167B (zh) 2024-03-19
US20230159560A1 (en) 2023-05-25
IL293191A (en) 2022-07-01
TW202132317A (zh) 2021-09-01
US12448396B2 (en) 2025-10-21
JP7698676B2 (ja) 2025-06-25
KR20220106159A (ko) 2022-07-28
AU2020392087A1 (en) 2022-06-09
CR20220308A (es) 2022-08-04
TWI867822B (zh) 2024-12-21
CL2022001357A1 (es) 2023-03-10
JP2023078418A (ja) 2023-06-06
US11512097B2 (en) 2022-11-29
IL293191B2 (en) 2025-09-01
TWI815061B (zh) 2023-09-11
US20210188874A1 (en) 2021-06-24
TW202409042A (zh) 2024-03-01
CL2023002486A1 (es) 2024-01-12
KR20230154292A (ko) 2023-11-07
EP4065223A1 (en) 2022-10-05
WO2021108408A1 (en) 2021-06-03
CN118161500A (zh) 2024-06-11
SA522432710B1 (ar) 2025-05-29
CN114728167A (zh) 2022-07-08
PH12022551282A1 (en) 2023-11-29
CO2022008690A2 (es) 2022-06-30
KR102598203B1 (ko) 2023-11-03
AR120556A1 (es) 2022-02-23
US20210221824A1 (en) 2021-07-22
PE20231097A1 (es) 2023-07-18
AU2020392087B2 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2023012725A (es) Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
UY31679A1 (es) Inhibidores de cinasa pim y metodos para su uso
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
NI201100137A (es) Derivados de sulfonamida
ECSP109953A (es) Derivados de piridazinona
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
AR056049A1 (es) 2-(2,6-dimetil-morfolin-4-il-n-[5-(6-morfolin-4-il-4-oxo-4h-piran-2-il)-9h-tioxanten-2-il]-acetamida,como inhibidor de la quinasa atm
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY38972A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CO2022000266A2 (es) Inhibidores de enzimas
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CL2023003921A1 (es) Inhibidores de transglutaminasas
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20260112